BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will
report its first quarter 2019 financial results on Thursday, April 25,
2019 after the close of financial markets. Following the announcement,
company management will host a conference call and webcast discussion of
the results and provide a general corporate update. Access to the event
can be obtained as follows:
LIVE access on Thursday, April 25, 2019
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
-
Telephone 877-260-1479 (domestic) or +1 334-323-0522 (international);
conference ID 6169352 -
Webcast with slides available at www.seattlegenetics.com
in the Investors
section
REPLAY access
-
Telephone replay will be available beginning at approximately 4:30
p.m. PT on Thursday, April 25, 2019 through 5:00 p.m. PT on Monday,
April 29, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820
(international); conference ID 6169352 -
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com
in the Investors
section
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes transformative
therapies targeting cancer to make a meaningful difference in people’s
lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s
industry-leading ADC technology and is currently approved for the
treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the
company has established a pipeline of novel targeted therapies at
various stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic urothelial
cancer and tisotumab vedotin for metastatic cervical cancer utilize our
proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase
inhibitor, is in a pivotal trial for HER2-positive metastatic breast
cancer. In addition, we are leveraging our expertise in empowered
antibodies to build a portfolio of proprietary immuno-oncology agents in
clinical trials targeting hematologic malignancies and solid tumors. The
company is headquartered in Bothell, Washington, and has a European
office in Switzerland. For more information on our robust pipeline,
visit www.seattlegenetics.com and
follow @SeattleGenetics on Twitter.
Contacts
Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
Media
Monique Greer
(425) 527-4641
mgreer@seagen.com